The literature on cognitive impairments associated with cancer treatment has accumulated in the past 15 years.1 Various reports have provided convincing evidence that chemotherapy (chemobrain) as well as other cancer treatments (eg, endocrine treatments for breast cancer) lead to significant cognitive impairments. Generally, researchers in this field emphasize the need to use objective measures of cognitive functioning to capture the “real” deficits. To that end, extensive batteries of neuropsychological tests have been used to identify which specific cognitive domains are affected by cancer treatment.2 To our knowledge, this idea has not been questioned. Herein, we argue that there are many contexts in which subjective measures would be more useful than neuropsychological tests. To support our argument, we provide a parallel example from sleep research.
Savard J, Ganz PA. Subjective or Objective Measures of Cognitive Functioning—What’s More Important?. JAMA Oncol. 2016;2(10):1263-1264. doi:10.1001/jamaoncol.2016.2047